Latest / Glaucoma, Vision & Longevity: Supplements & Science / A New Glaucoma Drug Study Is Starting: Could an Oral Cannabinoid Help Lower Eye Pressure?

Transcript

A New Glaucoma Drug Study Is Starting: Could an Oral Cannabinoid Help Lower Eye Pressure? · Glaucoma, Vision & Longevity: Supplements & Science

• 0:00
  SPEAKER_00: A new glaucoma drug study is starting.
• 0:02
  SPEAKER_00: Could an oral cannabinoid help lower eye pressure?
• 0:06
  SPEAKER_00: Some patients may have seen news on March 18, 2026, about a new drug trial for glaucoma and wondered what it means.
• 0:13
  SPEAKER_00: It's about a medicine called ART27.113, an experimental oral drug aimed at lowering eye pressure in people with glaucoma or ocular hypertension.
• 0:23
  SPEAKER_00: In simple terms, this is only a research study.
• 0:26
  SPEAKER_00: The drug is not FDA approved or proven to work yet.
• 0:29
  SPEAKER_00: It is being tested to see if it can safely lower the pressure inside the eye.
• 0:34
  SPEAKER_00: Before we dive in, let's remember why eye pressure matters.
• 0:37
  SPEAKER_00: Glaucoma is a group of eye conditions where high pressure or poor blood flow damages the optic nerve at the back of the eye.
• 0:45
  SPEAKER_00: That nerve damage causes vision loss.
• 0:48
  SPEAKER_00: Once vision is lost from glaucoma, it cannot be restored.
• 0:51
  SPEAKER_00: So doctors focus on slowing the damage, not fixing it.
• 0:55
  SPEAKER_00: The only proven way to slow glaucoma is by lowering the pressure in the eye.
• 0:59
  SPEAKER_00: Today this is usually done with eye drops or surgery.
• 1:03
  SPEAKER_00: A new study is exploring whether ART27.113, an oral drug, can join these treatments.
• 1:09
  SPEAKER_00: What is AR-2713?
• 1:12
  SPEAKER_00: AR27.13 is the code name for a new experimental drug.
• 1:16
  SPEAKER_00: It is related to cannabinoids, the kinds of active compounds found in the cannabis plant, but it is specially made in a lab.
• 1:23
  SPEAKER_00: It is taken by mouth, an oral tablet.
• 1:26
  SPEAKER_00: The reason researchers are interested is that some cannabinoids can lower eye pressure.
• 1:31
  SPEAKER_00: However, AR27.13 is not just cannabis.
• 1:35
  SPEAKER_00: It is designed to work mainly outside the brain.
• 1:38
  SPEAKER_00: In other words, it should not make someone feel high or have the same effects as marijuana.
• 1:43
  SPEAKER_00: Scientists hope it targets only the eye and body tissues involved in pressure.
• 1:48
  SPEAKER_00: No one can take R2713 outside a doctor's study right now.
• 1:53
  SPEAKER_00: It's only being given to volunteers in the trial.
• 1:56
  SPEAKER_00: Remember, this is early clinical research.
• 1:59
  SPEAKER_00: AR27.13 is not an approved medicine yet.
• 2:03
  SPEAKER_00: It is being studied to see if it is safe and if it can lower eye pressure.
• 2:07
  SPEAKER_00: We do not know if it will help.
• 2:09
  SPEAKER_00: That is exactly what the trial is meant to find out.
• 2:12
  SPEAKER_00: Why are cannabinoids of interest in glaucoma?
• 2:15
  SPEAKER_00: Cannabinoids have a long history in glaucoma research.
• 2:18
  SPEAKER_00: Many people know that marijuana can lower eye pressure a bit, at least for a few hours.
• 2:24
  SPEAKER_00: In fact, cannabis and related compounds have been known since the 1970s to temporarily reduce intraocular pressure.
• 2:31
  SPEAKER_00: Studies show that taking THC or synthetic cannabinoids by mouth can drop pressure by up to about 10 to 30 percent, but only for a few hours.
• 2:42
  SPEAKER_00: After that, the pressure goes back up.
• 2:44
  SPEAKER_00: One review found the maximum drop at 2 to 4 hours after dose, and it stopped in 3 to 4 hours.
• 2:51
  SPEAKER_00: Because of this, some researchers wondered if certain cannabinoids could help with glaucoma.
• 2:57
  SPEAKER_00: Cannabinoids also have other effects that might help.
• 3:00
  SPEAKER_00: They can improve blood flow to the optic nerve and may reduce inflammation.
• 3:04
  SPEAKER_00: But there are problems with using ordinary cannabis.
• 3:07
  SPEAKER_00: The drop in eye pressure is short-lived and would require dosing many times a day.
• 3:13
  SPEAKER_00: Meanwhile, marijuana causes side effects like feeling high, tiredness, and faster heartbeat.
• 3:19
  SPEAKER_00: Because of that, eye doctors do not use medical cannabis to treat glaucoma.
• 3:23
  SPEAKER_00: As one eye specialist explained, most glaucoma doctors believe marijuana is really ineffective for treating the disease.
• 3:31
  SPEAKER_00: This history has made the topic confusing for patients.
• 3:35
  SPEAKER_00: On one hand, you might hear that cannabis lowers eye pressure.
• 3:38
  SPEAKER_00: That is true technically, but you also hear that it's not a real cure for glaucoma.
• 3:44
  SPEAKER_00: For example, a recent expert review found no clear benefit of cannabis for glaucoma, it concluded there is only limited evidence and even suggested cannabinoids are not effective at improving eye pressure.
• 3:56
  SPEAKER_00: In short, the hype around cannabis and glaucoma has often outpaced the science.
• 4:02
  SPEAKER_00: Many claims about marijuana curing glaucoma come from old or incomplete data.
• 4:07
  SPEAKER_00: That is why a carefully designed drug trial like this one is needed to test a specific compound and measure its effect.
• 4:14
  SPEAKER_00: How is AR-2713 different from medical cannabis?
• 4:18
  SPEAKER_00: It's important to stress that AR27.13 is not the same as using medical marijuana.
• 4:24
  SPEAKER_00: Medical cannabis usually means whole plant products or extracts that contain things like THC and CBD.
• 4:30
  SPEAKER_00: Those can cause a psychoactive effect, the high.
• 4:34
  SPEAKER_00: AR27.113, by contrast, is a single molecule drug.
• 4:38
  SPEAKER_00: Think of it like the difference between a plant tea and a specific medicine pill.
• 4:43
  SPEAKER_00: This drug is made so that it can't get into the brain easily.
• 4:46
  SPEAKER_00: In effect, it should act only on the eye and body.
• 4:50
  SPEAKER_00: The goal is that patients won't feel any mind-altering effects.
• 4:53
  SPEAKER_00: For context, the FDA has approved a few cannabinoid-based drugs in other fields, for example, synthetic THC pills called dronabinol or nabilone and a pure CBD medicine.
• 5:04
  SPEAKER_00: But those are used for things like nausea from chemotherapy, not for glaucoma.
• 5:09
  SPEAKER_00: In glaucoma, an oral pill like ART 27.13 is very different from smoking or eating cannabis.
• 5:17
  SPEAKER_00: It's a new chemical aimed only at the eye's pressure system.
• 5:20
  SPEAKER_00: The new study, what was announced in March 2026.
• 5:24
  SPEAKER_00: In March 2026, researchers announced that they have approval to begin a clinical trial of ART 2713 for glaucoma and ocular hypertension.
• 5:33
  SPEAKER_00: Here are the key facts of this study.
• 5:36
  SPEAKER_00: Investigator-sponsored, it is led by doctors and scientists, likely at a university or hospital, rather than by a pharmaceutical company.
• 5:44
  SPEAKER_00: This often means it is a smaller, carefully controlled trial.
• 5:48
  SPEAKER_00: Randomized crossover design.
• 5:50
  SPEAKER_00: The study will randomly assign participants to get either AART 27.13 or a placebo for a time, and then switch crossover to the other treatment.
• 6:00
  SPEAKER_00: This way, each participant acts as their own comparison.
• 6:03
  SPEAKER_00: Researchers use this design to fairly compare the drug's effect to no treatment.
• 6:08
  SPEAKER_00: Regulatory approval.
• 6:10
  SPEAKER_00: The trial has been approved by an ethics board to protect participants and by the UK's Medicines and Healthcare Products Regulatory Agency, MHRA.
• 6:19
  SPEAKER_00: This means it meets safety and quality rules for clinical research.
• 6:24
  SPEAKER_00: Timeline.
• 6:25
  SPEAKER_00: The announcement said the study plans to enroll its first patient in the second quarter of 2026.
• 6:30
  SPEAKER_00: That means they hope to start seeing patients around spring 2026.
• 6:35
  SPEAKER_00: It's worth repeating, this trial is just beginning.
• 6:39
  SPEAKER_00: No results are available yet.
• 6:41
  SPEAKER_00: The doctors are checking if AR27.13 is safe and whether it can lower eye pressure in people.
• 6:46
  SPEAKER_00: At this stage, it is exploratory clinical research.
• 6:49
  SPEAKER_00: Could AR-2713 help lower eye pressure?
• 6:53
  SPEAKER_00: The hope is that it could.
• 6:55
  SPEAKER_00: We know by experience that the eye's pressure can be reduced by working on the same system that cannabinoids affect.
• 7:02
  SPEAKER_00: Past experiments, like giving volunteers THC or related drugs, did see a modest pressure drop.
• 7:09
  SPEAKER_00: Because AR-27.13 is a carefully made cannabinoid, scientists think it might also lighten the fluid pressure in the eye.
• 7:17
  SPEAKER_00: If the drug proves to safely cause a significant pressure drop, then in theory it could help protect vision over time, since lowering pressure is the only proven way to slow glaucoma.
• 7:28
  SPEAKER_00: However, we do not yet know if AR27.13 actually works this way.
• 7:34
  SPEAKER_00: Early studies can only tell us about safety and possible effects.
• 7:38
  SPEAKER_00: Even if pressure goes down a bit, doctors will need larger studies to confirm the benefit.
• 7:43
  SPEAKER_00: That's why this trial is small and initial.
• 7:45
  SPEAKER_00: Right now, we can't say it will lower pressure.
• 7:48
  SPEAKER_00: We have to wait for the study results.
• 7:50
  SPEAKER_00: Is ART27.13 the same as using medical cannabis?
• 7:55
  SPEAKER_00: No.
• 7:55
  SPEAKER_00: AR27.13 is not the same as smoking or using marijuana or other cannabis products.
• 8:01
  SPEAKER_00: The term medical cannabis generally refers to cannabis plant or plant extract containing THC, CBD, and other compounds.
• 8:08
  SPEAKER_00: AR-2713 is a single laboratory-made compound.
• 8:12
  SPEAKER_00: Taking medical cannabis by smoking, oil, or tincture often involves psychoactive THC and variable other chemicals, plus legal and health issues.
• 8:21
  SPEAKER_00: By contrast, ART 27.13 is a pill made to target eye pressure specifically.
• 8:27
  SPEAKER_00: Putting it another way, if you have glaucoma, using marijuana is not the same as enrolling in this study.
• 8:33
  SPEAKER_00: In fact, eye doctors do not recommend glaucoma patients rely on marijuana.
• 8:37
  SPEAKER_00: As noted above, studies and experts say marijuana's effects on glaucoma are not reliable or long-lasting.
• 8:44
  SPEAKER_00: The ART 27.13 study is testing a far more precise approach.
• 8:48
  SPEAKER_00: Could it restore lost vision?
• 8:51
  SPEAKER_00: No.
• 8:51
  SPEAKER_00: Like all glaucoma treatments, ART27.13, if it works, would only slow further damage, not bring back vision already lost.
• 8:59
  SPEAKER_00: Glaucoma damages the optic nerve, and nerve cells do not grow back.
• 9:04
  SPEAKER_00: Many eye doctors point out that glaucoma causes irreversible vision loss.
• 9:08
  SPEAKER_00: That's why the key goal is to preserve existing vision by lowering pressure.
• 9:13
  SPEAKER_00: If AR27.13 can lower pressure, it might help slow new damage, but it cannot make blind areas of vision come back.
• 9:21
  SPEAKER_00: Why this got attention?
• 9:22
  SPEAKER_00: This news got a lot of attention for a few reasons.
• 9:25
  SPEAKER_00: First, any story that mentions glaucoma and a new drug grabs interest from patients eager for breakthroughs.
• 9:32
  SPEAKER_00: Second, the word cannabinoid in an eye treatment is eye-catching.
• 9:37
  SPEAKER_00: Many people have heard bits and pieces about cannabis and eye pressure, which creates curiosity and confusion.
• 9:43
  SPEAKER_00: Media outlets know that inside and outside medicine, cannabis sells headlines.
• 9:48
  SPEAKER_00: Articles often play up the idea of cannabis for glaucoma, even though the scientific answer is unclear.
• 9:55
  SPEAKER_00: So when a press release speaks of an oral cannabinoid for glaucoma, it sounds like big news.
• 10:01
  SPEAKER_00: Patients and families who have struggled with glaucoma hear this and naturally wonder if it's the long-awaited cure.
• 10:09
  SPEAKER_00: That interest is understandable, but it's also why the story needs careful explanation.
• 10:15
  SPEAKER_00: Why patients should stay careful with the headlines.
• 10:18
  SPEAKER_00: It's important not to jump to conclusions from early news.
• 10:21
  SPEAKER_00: This study is just starting, and it does not mean ART27.13 is effective or approved.
• 10:27
  SPEAKER_00: Headlines may simplify things.
• 10:29
  SPEAKER_00: Cannabis helps glaucoma, for example, is a phrase you might see, but that is not proven.
• 10:34
  SPEAKER_00: In reality, most eye specialists say exactly the opposite in terms of glaucoma management.
• 10:39
  SPEAKER_00: As one doctor put it bluntly, marijuana is really ineffective in the management of glaucoma.
• 10:45
  SPEAKER_00: The confusion comes from mixing up a few facts.
• 10:48
  SPEAKER_00: Yes, cannabinoid chemistry can lower pressure briefly, but it's not a treatment that doctors currently use for glaucoma.
• 10:56
  SPEAKER_00: Headlines can gloss over the fact that this is an early trial, not a success story.
• 11:02
  SPEAKER_00: For now, AR27.13 has been announced for study, but no patient data are public.
• 11:08
  SPEAKER_00: Glaucoma patients should continue their regular treatments and follow-up with their eye doctors.
• 11:14
  SPEAKER_00: In short, stay careful with the excitement online.
• 11:18
  SPEAKER_00: This announcement is newsworthy, but it's not the end of the story.
• 11:21
  SPEAKER_00: Researchers himself emphasize caution.
• 11:23
  SPEAKER_00: Until the study is done, we won't know if ART27113 really does anything useful for glaucoma.
• 11:30
  SPEAKER_00: Eye doctors always say, watch out for claims that sound too good to be true.
• 11:34
  SPEAKER_00: What would need to happen next if this drug shows promise?
• 11:38
  SPEAKER_00: If this trial finds that AR-2713 substantially and safely lowers eye pressure, it would be a first step.
• 11:46
  SPEAKER_00: The next steps would be typical for any new medicine.
• 11:49
  SPEAKER_00: The researchers would need to do larger studies, often called phase two and phase three trials, involving more patients and many clinics.
• 11:57
  SPEAKER_00: These would confirm the effect and look for any rare side effects.
• 12:01
  SPEAKER_00: Only after robust evidence in those trials could the company or investigators apply for official approval.
• 12:08
  SPEAKER_00: That process can take years of work.
• 12:10
  SPEAKER_00: In other words, even if AR-2713 looks promising, it would still be a long road before it could become a real treatment option.
• 12:19
  SPEAKER_00: Patients should watch for future study results, but continue trusting the glaucoma treatments their doctors have recommended.
• 12:26
  SPEAKER_00: Key takeaway AR27.3T is an experimental oral drug derived from cannabinoid chemistry.
• 12:34
  SPEAKER_00: It is now being tested in a carefully approved clinical trial starting around spring 2026 to see if it can safely lower eye pressure in glaucoma.
• 12:44
  SPEAKER_00: This is early research, not a cure.
• 12:46
  SPEAKER_00: While cannabinoids have known pressure-lowering effects, those were short-lived and not practical as therapy.
• 12:53
  SPEAKER_00: ART27.13 is made to avoid psychoactive side effects, but its effectiveness is still unknown.
• 12:59
  SPEAKER_00: Keep an eye on updates, but for now rely on proven treatments to protect vision.
• 13:04
  SPEAKER_00: Sources, research and expert reviews on cannabinoids and glaucoma, official glaucoma patient information, eye care professional publications on cannabis.
• 13:15
  SPEAKER_00: Press coverage of the new study announcement.
• 13:17
  SPEAKER_00: All links to sources are available in the text version of this article.
• 13:22
  SPEAKER_00: You can find the full article at VisualFieldTest.com.
• 13:25
  SPEAKER_00: Thanks for listening.
• 13:27
  SPEAKER_00: To check your visual field, click the link at the bottom of this article or visit visualfieldtest.com.